Agenus (AGEN) Liabilities and Shareholders Equity (2010 - 2026)
Agenus (AGEN) posted quarterly Liabilities and Shareholders Equity of $186.5 million for Q1 2026, down 6.87% year-over-year from $200.2 million in Q1 2025, and down 17.79% quarter-over-quarter from $226.8 million in Q4 2025.
Agenus (AGEN) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Agenus' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $186.5 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 6.87% year-over-year to $186.5 million; the TTM figure through Mar 2026 stood at $832.4 million (down 13.06% YoY), while the FY2025 annual figure was $226.8 million, changed 0.23% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $186.5 million, down from $226.8 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $456.2 million in Q2 2022, with the low at $185.2 million in Q2 2025.
- The 5-year median for Liabilities and Shareholders Equity is $292.4 million (2024), against an average of $307.8 million.
- The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity surged 137.22% in 2022, then sank 37.86% in 2024.
- Agenus' Liabilities and Shareholders Equity stood at $413.6 million in 2022, then decreased by 24.09% to $313.9 million in 2023, then dropped by 27.92% to $226.3 million in 2024, then advanced by 0.23% to $226.8 million in 2025, then decreased by 17.79% to $186.5 million in 2026.
- Business Quant data shows AGEN's Liabilities and Shareholders Equity at $186.5 million in Q1 2026, $226.8 million in Q4 2025, and $233.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Agenus | 311.95 Mn | 286.43 Mn | 34.52 Mn | 172.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 172.69 Mn |
| Mar 31, 2026 | 186.46 Mn |
| Dec 31, 2025 | 226.80 Mn |
| Sep 30, 2025 | 233.89 Mn |
| Jun 30, 2025 | 185.22 Mn |
| Mar 31, 2025 | 200.20 Mn |
| Dec 31, 2024 | 226.27 Mn |
| Sep 30, 2024 | 238.48 Mn |
| Jun 30, 2024 | 292.42 Mn |
| Mar 31, 2024 | 256.56 Mn |
| Dec 31, 2023 | 313.91 Mn |
| Sep 30, 2023 | 335.47 Mn |
| Jun 30, 2023 | 383.59 Mn |
| Mar 31, 2023 | 412.85 Mn |
| Dec 31, 2022 | 413.56 Mn |
| Sep 30, 2022 | 429.02 Mn |
| Jun 30, 2022 | 456.17 Mn |
| Mar 31, 2022 | 441.31 Mn |
| Dec 31, 2021 | 465.96 Mn |
| Sep 30, 2021 | 437.64 Mn |